Table 1 The characteristics of the studies those were included in Ethiopia, 2022
Authors (Year) | Region | Study design | Mean/median age (year) | Sample size | HIV/Tb co-infection status | Total prevalence of hepatotoxicity (%) | Overall hepatotoxicity on treatment naïve (%) | Overall hepatotoxicity on ART (%) | Degree of hepatotoxicity | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
Mild (%) | Moderate (%) | Severe (%) | |||||||||
Yazie (2021) [31] | Addis Ababa | Prospective cohort | 39.7 ± 10 | 63 | HIV | 41.3 | NA | 41.3 | 38.2 | 3.2 | NA |
Baynes et al. (2017) [32] | Amhara | Retrospective cohort | NA | 275 | HIV | 23.3 | 6.5 | 23.2 | 2.2 | 10.9 | 3.6 |
Shiferaw et al. (2016) [33] | Amhara | Cross-sectional | 36.29 ± 10.27 | 328 | HIV | 12.2 | 22 | 20.1 | 6.7 | 3.7 | 3 |
Mulu et al. (2013) [34] | Amhara | Cross-sectional | 35 | 269 | HIV | 32 | NA | 32 | 22.3 | 7.8 | 1.84 |
Tesfa et al. (2019) [35] | Amhara | Cross-sectional | 37.37 | 152 | HIV | 17.1 | 9.2 | 25 | 23.7 | 1.3 | NA |
Gebremicael et al. (2021) [36] | Addis Ababa | Prospective cohort | 32 | 316 | HIV/Tb | 29.1 | 22.8 | 38 | 21.7 | 9.6 | 1.2 |
Woldu et al. (2014) [37] | Tigray | Case–control | 33.6 ± 17 | 100 | HIV/Tb | 60 | NA | 55 | 45 | 8 | 7 |
Yimer et al. (2014) [38] | Addis Ababa | Prospective cohort | NA | 1060 | HIV/Tb | 15 | NA | 15 | 8.02 | 4.9 | 2.08 |
Yimer et al. (2011) [39] | Addis Ababa | Prospective cohort | NA | 353 | HIV/Tb | 30 | NA | 30 | NA | 11.6 | 18.4 |
Yimer et al. (2012) [40] | Addis Ababa | Prospective cohort | 34 | 285 | HIV/Tb | 24.1 | 8.4 | 15.7 | NA | 11.6 | 18.4 |
Hassen Ali et al. (2013) [41] | Oromia | Case–control | 32.1 ± 8.5 | 288 | HIV/Tb | 11.5 | NA | NA | 6.3 | NA | 5.2 |
Zeleke et al. (2020) [42] | Amhara | Cross-sectional | NA | 84 | HIV/Tb | 20.2 | NA | NA | NA | NA | NA |
Yimer et al. (2008) [43] | Addis Ababa | Prospective cohort | NA | 103 | HIV/Tb | 25.2 | NA | NA | NA | NA | NA |